ARCT

ARCT

USD

Arcturus Therapeutics Holdings Inc. Common Stock

$8.930-0.240 (-2.617%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$9.170

高値

$9.400

安値

$8.840

出来高

1.18M

企業ファンダメンタルズ

時価総額

242.5M

業種

バイオテクノロジー

United States

取引統計

平均出来高

1.22M

取引所

NGM

通貨

USD

52週レンジ

安値 $8.04現在値 $8.930高値 $24.17

関連ニュース

Analyst Upgrades

HC Wainwright & Co. Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12

HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $60 to $12.

もっと見る
HC Wainwright & Co. Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
Analyst Upgrades

Citigroup Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12

Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $49 to $12.

もっと見る
Citigroup Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
Analyst Upgrades

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.

もっと見る
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
Analyst Upgrades

BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $23

BTIG analyst Thomas Shrader maintains Arcturus Therapeutics with a Buy and lowers the price target from $48 to $23.

もっと見る
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $23
Analyst Upgrades

Guggenheim Downgrades Arcturus Therapeutics to Neutral

Guggenheim analyst Seamus Fernandez downgrades Arcturus Therapeutics from Buy to Neutral.

もっと見る
Guggenheim Downgrades Arcturus Therapeutics to Neutral
BusinessWire

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants